Journal•ISSN: 1936-3761
Current Fungal Infection Reports
Springer Science+Business Media
About: Current Fungal Infection Reports is an academic journal published by Springer Science+Business Media. The journal publishes majorly in the area(s): Aspergillosis & Voriconazole. It has an ISSN identifier of 1936-3761. Over the lifetime, 522 publications have been published receiving 5014 citations.
Topics: Aspergillosis, Voriconazole, Medicine, Population, Posaconazole
Papers published on a yearly basis
Papers
More filters
TL;DR: Methods developed for testing filamentous fungi (molds) include standardized broth microdilution methods and disk diffusion methods and the link between resistance molecular mechanisms, elevated MICs, and clinical treatment failure has been documented.
Abstract: Methods developed for testing filamentous fungi (molds) include standardized broth microdilution (Clinical and Laboratory Standards Institute [CLSI] and European Committee for Antimicrobial Susceptibility Testing [AFST-EUCAST]) methods and disk diffusion (CLSI) methods. Quality control limits also are available from CLSI for MIC (minimal inhibitory concentration), MEC (minimal effective concentration), and zone diameters. Although clinical breakpoints based on correlations of in vitro results with clinical outcome have not been established, epidemiologic cutoff values have been defined for six Aspergillus species and the triazoles, caspofungin, and amphotericin B. The link between resistance molecular mechanisms, elevated MICs, and clinical treatment failure has also been documented, especially for Aspergillus and the triazoles. Other insights into the potential clinical value of high MICs have also been reported. Various commercial methods (e.g., YeastOne, Etest, and Neo-Sensitabs) have been evaluated in comparison with reference methods. This review summarizes and discusses these developments.
248 citations
TL;DR: This review will discuss current diagnostic modalities of fungal keratitis and will particularly focus on treatment regimens, and explore future therapeutic models and critique the potential benefit of each.
Abstract: Fungal keratitis remains a challenging and often elusive diagnosis in geographic regions where it is endemic. Marred by delays in diagnosis, the sequelae of corneal fungal infections, though preventable, can be irreversible. Recent studies and advances in the arena have broadened the approach and treatment to mycotic keratitis. This review will discuss current diagnostic modalities of fungal keratitis and will particularly focus on treatment regimens. It will also explore future therapeutic models and critique the potential benefit of each.
214 citations
TL;DR: The spectrum of etiological agents causing mucormycosis is unique as Apophysomyces elegans is the second most common pathogen after Rhizopus oryzae and many new agents are identified causing the disease.
Abstract: Mucormycosis is an emerging healthcare problem in the Indian population. The epidemiology of the disease is distinct with very high incidence among uncontrolled diabetics. The patients present commonly as rhino-orbito-cerebral mucormycosis, which is easy to diagnose. But, the mortality rate remains high (nearly 50 %), as the patients attend the healthcare facility late in the course of the disease after extensive spread of infection. Isolated renal mucormycosis in young apparently healthy individuals is a new form of the disease. The spectrum of etiological agents causing mucormycosis is also unique as Apophysomyces elegans is the second most common pathogen after Rhizopus oryzae. Many new agents are identified causing the disease.
203 citations
TL;DR: The most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections are highlighted and the challenges associated with TDM are referred to.
Abstract: Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.
112 citations
TL;DR: An extensive search of medical literature from Latin America suggests that the incidence of IFIs from both endemic and opportunistic fungi has increased, which is probably related to population changes (migration, tourism, and increased population growth), whereas the increase in opportunistic mycoses may be associated with the greater number of people at risk.
Abstract: The pathogenic role of invasive fungal infections (IFIs) has increased during the past two decades in Latin America and worldwide, and the number of patients at risk has risen dramatically. Working habits and leisure activities have also been a focus of attention by public health officials, as endemic mycoses have provoked a number of outbreaks. An extensive search of medical literature from Latin America suggests that the incidence of IFIs from both endemic and opportunistic fungi has increased. The increase in endemic mycoses is probably related to population changes (migration, tourism, and increased population growth), whereas the increase in opportunistic mycoses may be associated with the greater number of people at risk. In both cases, the early and appropriate use of diagnostic procedures has improved diagnosis and outcome.
91 citations